Plant-derived antivirals against hepatitis c virus infection

Jardim, Ana Carolina Gomes; Shimizu, Jacqueline Farinha; Rahal, Paula; Harris, Mark

doi:10.1186/s12985-018-0945-3

Cited by 30 publications

(21 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, might act by interfering with bioassays through several mechanisms and are termed Pan Assay INterference compoundS (PAINS) [102,103] , whic h may affect the obtained bioassays results’ credibility and, thus, should be carefully analyzed [104] .…”

Section: Naringenin In Clinical Trialsmentioning

confidence: 99%

The Therapeutic Potential of Naringenin: A Review of Clinical Trials

et al. 2019

View full text Add to dashboard Cite

Naringenin is a flavonoid belonging to flavanones subclass. It is widely distributed in several Citrus fruits, bergamot, tomatoes and other fruits, being also found in its glycosides form (mainly naringin). Several biological activities have been ascribed to this phytochemical, among them antioxidant, antitumor, antiviral, antibacterial, anti-inflammatory, antiadipogenic and cardioprotective effects. Nonetheless, most of the data reported have been obtained from in vitro or in vivo studies. Although some clinical studies have also been performed, the main focus is on naringenin bioavailability and cardioprotective action. In addition, these studies were done in compromised patients (i.e., hypercholesterolemic and overweight), with a dosage ranging between 600 and 800 μM/day, whereas the effect on healthy volunteers is still debatable. In fact, naringenin ability to improve endothelial function has been well-established. Indeed, the currently available data are very promising, but further research on pharmacokinetic and pharmacodynamic aspects is encouraged to improve both available production and delivery methods and to achieve feasible naringenin-based clinical formulations.

show abstract

Section: Naringenin In Clinical Trialsmentioning

confidence: 99%

The Therapeutic Potential of Naringenin: A Review of Clinical Trials

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Therefore, natural compounds extracted from plants have attracted the attention of researchers for their therapeutic activities. 6 A substantial variety of natural compounds has demonstrated antiviral activity, including against HCV, 7 or hepatoprotective effect from natural compounds like naringenin, epigallocatechin-3-gallate (EGCG), silymarin, and caffeine. 8,9 Turmeric curcumin, known as curcuma longa, is a natural plant with a significant therapeutic role that harbors no side effects.…”

Section: Introductionmentioning

confidence: 99%

<p>Antiviral Activity of Chitosan Nanoparticles Encapsulating Curcumin Against Hepatitis C Virus Genotype 4a in Human Hepatoma Cell Lines</p>

Loutfy¹,

Elberry²,

Farroh³

et al. 2020

IJN

View full text Add to dashboard Cite

Purpose: Current direct-acting antiviral agents for treatment of hepatitis C virus genotype 4a (HCV-4a) have been reported to cause adverse effects, and therefore less toxic antivirals are needed. This study investigated the role of curcumin chitosan (CuCs) nanocomposite as a potential anti-HCV-4a agent in human hepatoma cells Huh7. Methods: Docking of curcumin and CuCs nanocomposite and binding energy calculations were carried out. Chitosan nanoparticles (CsNPs) and CuCs nanocomposite were prepared with an ionic gelation method and characterized with TEM, zeta size and potential, and HPLC to calculate encapsulation efficiency. Cytotoxicity studies were performed on Huh7 cells using MTT assay and confirmed with cellular and molecular assays. Anti-HCV-4a activity was determined using real-time PCR and Western blot. Results: The strength of binding interactions between protein ligand complexes gave scores with NS3 protease, NS5A polymerase, and NS5B polymerase of -124.91, -159.02, and -129.16, for curcumin respectively, and -68.51, -54.52, and -157.63 for CuCs nanocomposite, respectively. CuCs nanocomposite was prepared at sizes 29-39.5 nm and charges of 33 mV. HPLC detected 4% of curcumin encapsulated into CsNPs. IC50 was 8 µg/mL for curcumin and 25 µg/ mL for the nanocomposite on Huh7 but was 25.8 µg/mL and 34 µg/mL on WISH cells. CsNPs had no cytotoxic effect on tested cell lines. Apoptotic genes' expression revealed the caspasedependent pathway mechanism. CsNPs and CuCs nanocomposite demonstrated 100% inhibition of viral entry and replication, which was confirmed with HCV core protein expression. Conclusion: CuCs nanocomposite inhibited HCV-4a entry and replication compared to curcumin alone, suggesting its potential role as an effective therapeutic agent. Plain Language SummaryHepatitis C virus genotype 4a (HCV-4a) is a major public health problem, especially among the Egyptian population. There are more than 70 million individuals infected worldwide. It is the leading cause of chronic liver diseases, cirrhosis, and hepatocellular carcinoma. Newly emerged anti-HCV viral agents have recently become available on the market but with serious complications, high cost, and possible development of resistance. This has encouraged scientists to search for alternative, safer antiviral approaches. Nanoparticles offer unique physical properties that have associated benefits for antimicrobial activity or as drug carrier that can improve antiviral therapy. The significance of our research is in establishment of a natural nanoparticle drug carrier system that we screened with computer simulation studies and in cells against HCV-4a replication into human hepatoblastoma cell

show abstract

“…[62]. The inhibitory acitivity of Apigenin on HCV replication was reported in 2018 [63]. Herbs have a key role in managing different disorders of liver.…”

Section: Discussionmentioning

confidence: 99%

Anti-viral effect of Indigoferra gerardiana on core protein of HCV and clinical significance of serum markers in chronic HCV genotype 3a patients in district Peshawar

Mumtaz¹,

Ahmed²,

Tariq³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background/aim: Hepatitis C virus (HCV) disease is a health challenge due resistance cases globally. Many plant-derived natural compounds have demonstrated antiviral effects. These plants can provide an alternative way to new antiviral. Core protein of HCV has ability to interact with a wide range of viral and cellular proteins, including proto-oncogenes. Materials and Methods: In this cross-sectional study, total of 421 Hepatitis C Virus (HCV) positive patients were subjected by Polymerase Chain Reaction (PCR). The correlation of genotype with continuous and categorical variables was analyzed. Furthermore, antiviral activity of indigoferra gerardiana (IG) was tested against core protein of HCV. The amplified complete core protein of HCV genotype 3a was sequenced and cloned. IG was extracted and screened against core protein of HCV 3a genotype in cell line. Results: Genotype 3a was the common genotype type of HCV (n=363, 86%). Significant differences were observed in viral load among 3a genotype of HCV (< P 0.05). Frequently detected age group was 21-40 (59.4%) Sex and age were statistically associated with HCV infection (49% males and 37% in females). The results of RT-PCR demonstrated that methanolic extract of IG showed 57% reduction of infecting cells. Conclusions: Methanolic extract of IG showed good antiviral activity i.e. 57% reduction of infecting cells.

show abstract

Plant-derived antivirals against hepatitis c virus infection

Cited by 30 publications

References 132 publications

The Therapeutic Potential of Naringenin: A Review of Clinical Trials

The Therapeutic Potential of Naringenin: A Review of Clinical Trials

<p>Antiviral Activity of Chitosan Nanoparticles Encapsulating Curcumin Against Hepatitis C Virus Genotype 4a in Human Hepatoma Cell Lines</p>

Anti-viral effect of Indigoferra gerardiana on core protein of HCV and clinical significance of serum markers in chronic HCV genotype 3a patients in district Peshawar

Contact Info

Product

Resources

About